机构：[1]Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA[2]Department of Medicine, Harvard Medical School, Boston, MA, USA[3]Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA[4]Ludwig Center, Harvard Medical School, Boston,MA, USA[5]Department of Transplantation Immunology, Maastricht University Medical Center+, Maastricht, the Netherlands[6]School for Oncology andDevelopmental Biology, Maastricht University Medical Center+ GROW, Maastricht, the Netherlands[7]Department of Cell Biology, Harvard Medical School,Boston, MA, USA[8]Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA[9]Microsoft Research, Cambridge,MA, USA[10]Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland[11]Translational ImmunologyResearch Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland[12]iCAN Digital Precision Cancer MedicineFlagship, Helsinki, Finland[13]Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA[14]Department of Biostatistics, Harvard TH ChanSchool of Public Health, Boston, MA, USA[15]Present address: Sichuan University, Chengdu, China
This work was supported by the Stand Up To Cancer (SU2C) Convergence 2.0 Grant
(M.S., A.C.C., C.S.M.), a collaboration by SU2C and the Society for Immunotherapy
of Cancer; the SU2C Phillip A. Sharp Award for Innovation in Collaboration (grant
number: SU2C-AACR-PS-22) (M.S., C.S.M.); the Claudia Adams Barr Program in
Innovative Basic Cancer Research at Dana–Farber Cancer Institute (M.S., E.D., C.S.M.,
E.L.); the Human Frontier Science Program (HFSP) Fellowship (LT000834/2014-L,
M.S.); the Leukemia and Lymphoma Society (LLS) Scholar Award (C.S.M.); and the
Ludwig Center at Harvard (C.S.M.). The collaborating laboratories have also been
partially supported by grants NIH R01 CA050947 (C.S.M.), CA196664 (C.S.M.) and
U01 CA225730 (C.S.M.); de Gunzburg Myeloma Research Fund (C.S.M.); International
Myeloma Society (C.S.M.), the Shawna Ashlee Corman Investigatorship in Multiple
Myeloma Research (C.S.M.); Cobb Family Myeloma Research Fund (C.S.M.); the
Department of Defense grants W81XWH-15-1-0012 (C.S.M.) and W81XWH-15-1-0013
(A.C.); the Finnish Cancer Organizations, Sigrid Juselius Foundation, Academy of
Finland (S.M.); the Health Foundation Limburg, Nijbakker-Morra Stichting (N.B.); and
the Dutch Cancer Association (KWF Kanker Bestrijding, UM2012-5375) (L. Wieten).
We thank M. Sade-Feldman for technical advice and discussion, A. Rotem for the gift of
Malme-3M cell line and Y. Maruvka for assistance with MSI profiling.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类|1 区生物学
小类|1 区遗传学
最新[2023]版：
大类|1 区生物学
小类|1 区遗传学
第一作者：
第一作者机构：[1]Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA[2]Department of Medicine, Harvard Medical School, Boston, MA, USA[3]Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA[4]Ludwig Center, Harvard Medical School, Boston,MA, USA
通讯作者：
通讯机构：[1]Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA[2]Department of Medicine, Harvard Medical School, Boston, MA, USA[3]Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard, Cambridge, MA, USA[4]Ludwig Center, Harvard Medical School, Boston,MA, USA
推荐引用方式(GB/T 7714)：
Michal Sheffer,Emily Lowry,Nicky Beelen,et al.Genome-scale screens identify factors regulating tumor cell responses to natural killer cells.[J].Nature genetics.2021,53(8):1196-1206.doi:10.1038/s41588-021-00889-w.
APA：
Michal Sheffer,Emily Lowry,Nicky Beelen,Minasri Borah,Suha Naffar-Abu Amara...&Constantine S. Mitsiades.(2021).Genome-scale screens identify factors regulating tumor cell responses to natural killer cells..Nature genetics,53,(8)
MLA：
Michal Sheffer,et al."Genome-scale screens identify factors regulating tumor cell responses to natural killer cells.".Nature genetics 53..8(2021):1196-1206
生物学